The international trade in biotech products boosts national economies and advances scientific as well as technology innovation. However, while trading these products increases the spread of benefits on a global scale, it also increases risks to human health and the environment (ie biosafety). This is because the effects of this technology on biosafety are still highly uncertain. Against this background, the judicial bodies under the World Trade Organization (WTO) find themselves in the middle of an intricate and polarised debate in which a proper judicial balance between free trade and biosafety becomes fundamental in order to determine whether requests for ensuring human and environmental health justify trade restrictions. This paper aims to highlight that the WTO is institutionally unready for balancing economic and non-economic values. In suggesting how to rationalise the judicial balance between the competing interests in the context of biotechnology, this paper demonstrates that the judicial adoption of a well-structured proportionality analysis can turn the current balance by chance into a balance by structure.

中文翻译：

---

生物技术国际贸易法律纠纷的推理结构：从偶然的司法平衡到设计的司法平衡

生物技术产品的国际贸易促进了国民经济，推动了科学和技术创新。然而，虽然这些产品的交易增加了全球范围内的利益传播，但它也增加了对人类健康和环境（即生物安全）的风险。这是因为这项技术对生物安全的影响仍然高度不确定。在此背景下，世界贸易组织 (WTO) 下的司法机构陷入了一场错综复杂且两极分化的辩论之中，在这场辩论中，自由贸易和生物安全之间的适当司法平衡变得至关重要，以确定是否要求确保人类和环境安全。健康证明贸易限制是正当的。本文旨在强调世贸组织在制度上尚未准备好平衡经济和非经济价值。